Risk factor
Low price volatility
Profitability factor
Strong margins and returns
About
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers various FDs, such as tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; and other specialty products for oncology. The Company also exports its products. Granules India Limited was founded in 1984 and is based in Hyderabad, India.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E
Target Price
The average target price of GRANULES.NS is 587 and suggests 15% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation
Buy
Sell